PATRYS LIMITED - Announcements

Market Cap $18.51M Add to my watchlist

Healthcare Biotechnology

Patrys Limited is an Australia-based company, which is focused on the development of its... Patrys Limited is an Australia-based company, which is focused on the development of its deoxymab platform of cell-penetrating antibodies as therapies for a range of different cancers. The Company's deoxymab platform is based on the deoxymab 3E10 antibody that was identified as an autoantibody in a mouse model of the human disease systemic lupus erythematosus. It has developed two humanized forms of deoxymab 3E10, both of which have improved activity over the original deoxymab 3E10 antibody: PAT-DX1, which is a dimer (two joined subunits) of the short chain from the binding domain of deoxymab 3E10, and PAT-DX3, which is a full-sized Immunoglobulin G antibody. Deoxymabs, such as PAT-DX1 and PAT-DX3, can be used to target nanoparticles carrying a payload of anti-cancer drugs specifically to tumors. Its PAT-DX1- nanoparticles (NP) pipeline involves using its PAT-DX1 to develop a new drug based on the targeted delivery of NP carrying therapeutic payloads to the inside of cancer cells.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile

See benefits

Announcements

Filter Results

All Price Sensitive Only

PAB	Appendix 4C - Quarterly - 31 December 2014	PRICE SENSITIVE	09/01/15	157.96KB	Share
PAB	Becoming a substantial holder		08/12/14	724.87KB	Share
PAB	Patrys Presents at AusBiotech Invest 2014		03/12/14	569.96KB	Share
PAB	Initial Director's Interest Notice		12/11/14	278.96KB	Share
PAB	Results of Meeting		12/11/14	437.43KB	Share
PAB	Dr. James Campbell Joins the Patrys Board		12/11/14	428.44KB	Share
PAB	Patrys 2014 AGM Presentation		12/11/14	475.79KB	Share
PAB	Patrys Provides Update on Clinical Trial	PRICE SENSITIVE	07/11/14	426.23KB	Share
PAB	Final Director's Interest Notice - M Roskrow		29/10/14	189.25KB	Share
PAB	Patrys Provides Update on CEO Position	PRICE SENSITIVE	29/10/14	416.77KB	Share
PAB	Appendix 4C - Quarterly - 30 September 2014	PRICE SENSITIVE	17/10/14	157.58KB	Share
PAB	Notice of Annual General Meeting/Proxy Form		10/10/14	443.86KB	Share
PAB	Patrys Granted Australian Patent for PAT-LM1	PRICE SENSITIVE	30/09/14	359.8KB	Share
PAB	Patrys CEO Resignation	PRICE SENSITIVE	24/09/14	334.26KB	Share
PAB	Patrys Investor Presentation - September 2014		18/09/14	1.27MB	Share
PAB	Patrys Limited - Open Briefing	PRICE SENSITIVE	16/09/14	274.54KB	Share
PAB	Patrys 2014 Annual Report		09/09/14	1.41MB	Share
PAB	Preliminary Final Report - 30 June 2014	PRICE SENSITIVE	29/08/14	674.61KB	Share
PAB	Patrys - Details of PAT-SM6 & Carfilzomib Clinical Trial	PRICE SENSITIVE	25/08/14	370.28KB	Share
PAB	Patrys to Present at German Hematology Congress	PRICE SENSITIVE	18/08/14	124.94KB	Share
PAB	Patrys Reports Progress on Preclinical Programmes	PRICE SENSITIVE	24/07/14	476.88KB	Share
PAB	Appendix 4C - Quarterly Cash Flow - June 2014	PRICE SENSITIVE	21/07/14	156.5KB	Share
PAB	Patrys Granted Third US Patent for PAT-SM6	PRICE SENSITIVE	18/06/14	477.49KB	Share
PAB	Patrys' CEO Presents at Asia Biotech Invest 2014		04/06/14	1.39MB	Share
PAB	Positive Response for PAT-SM6 in Combination Therapy	PRICE SENSITIVE	28/05/14	371.59KB	Share
PAB	Appendix 3B		20/05/14	763KB	Share
PAB	Appendix 4C - Quarterly Cash Flow - March 2014	PRICE SENSITIVE	11/04/14	156.81KB	Share
PAB	First Plant-based Production of PAT-SM6	PRICE SENSITIVE	02/04/14	511.31KB	Share
PAB	Final Data Confirms Successful PAT-SM6 Clinical Trial	PRICE SENSITIVE	27/03/14	378.18KB	Share
PAB	PAT-LM1 Advancing to the Clinic	PRICE SENSITIVE	24/03/14	383.58KB	Share
PAB	Share Issue and Cleansing Statement		18/03/14	908.71KB	Share
PAB	Half Yearly Report and Accounts - December 2013	PRICE SENSITIVE	12/02/14	856.34KB	Share
PAB	Patrys Raises a Further $0.9 Million		29/01/14	1.09MB	Share
PAB	Patrys Provides Shareholder Update	PRICE SENSITIVE	23/01/14	490.29KB	Share
PAB	PAT-SC1 Clinical Trial 10 Year Follow Up Data Published	PRICE SENSITIVE	22/01/14	366.1KB	Share
PAB	Appendix 4C - Quarterly Cash Flow - December 2013	PRICE SENSITIVE	21/01/14	156.59KB	Share
PAB	Patrys Raises a Further $1.3 Million	PRICE SENSITIVE	14/01/14	911.84KB	Share
PAB	Change in substantial holding		06/01/14	388.05KB	Share
PAB	Change in substantial holding		20/12/13	95.95KB	Share
PAB	Change of Director's Interest Notice		19/12/13	204.5KB	Share
PAB	Change of Director's Interest Notice		19/12/13	204.68KB	Share
PAB	Change of Director's Interest Notice		19/12/13	206.13KB	Share
PAB	Change of Director's Interest Notice		19/12/13	208.12KB	Share
PAB	Appendix 3B - Rights Issue		19/12/13	492.32KB	Share
PAB	Patrys Raises $5.5m from Rights Issue		16/12/13	288.41KB	Share
PAB	Data from Final Cohort of Patients in MM Clinical Trial	PRICE SENSITIVE	29/11/13	483.66KB	Share
PAB	Rights Issue Offer Documents Mailed to Shareholders		27/11/13	247.52KB	Share
PAB	Rights Issue Offer Document	PRICE SENSITIVE	27/11/13	462.17KB	Share
PAB	Appendix 3B		20/11/13	488.94KB	Share
PAB	Patrys Presents at BBY Life Sciences Conference		19/11/13	1.22MB	Share
PAB	Patrys Granted Australian Patent for PAT-SM6	PRICE SENSITIVE	18/11/13	365.15KB	Share
PAB	Appendix 3B		15/11/13	488.37KB	Share
PAB	Appendix 3B		14/11/13	488.12KB	Share
PAB	Letter to Ineligible Shareholders		14/11/13	340.63KB	Share
PAB	Letter to Eligible Shareholders		14/11/13	180.24KB	Share
PAB	Letter to Optionholders		13/11/13	145.93KB	Share
PAB	Cleansing Statement		13/11/13	326.45KB	Share
PAB	Appendix 3B		13/11/13	493.33KB	Share
PAB	Patrys Announces $12.5 Million Rights Issue	PRICE SENSITIVE	13/11/13	408.37KB	Share
PAB	Patrys to Initiate Clinical Trial with Onyx Pharmaceuticals	PRICE SENSITIVE	11/11/13	469.72KB	Share
PAB	Patrys Granted US Patent for Lead Product PAT-LM1	PRICE SENSITIVE	08/11/13	355.39KB	Share
PAB	USA FDA Grants Orphan Drug Status for PAT-SM6	PRICE SENSITIVE	06/11/13	361.86KB	Share
PAB	Final Director's Interest Notice		23/10/13	236.64KB	Share
PAB	Results of Meeting		23/10/13	512.3KB	Share
PAB	CEO Presentation to 2013 AGM		23/10/13	964.21KB	Share
PAB	Appendix 4C - Quarterly Cash Flow - September 2013	PRICE SENSITIVE	18/10/13	34.88KB	Share
PAB	Retirement of Director - Dr. Alan Robertson		18/10/13	420.63KB	Share
PAB	Patrys Limited - Open Briefing		14/10/13	128.88KB	Share
PAB	Patrys to Present at ASH International Conference		10/10/13	481.72KB	Share
PAB	Patrys CEO Presents at BIO Investor Forum		09/10/13	1.83MB	Share
PAB	Notice of Annual General Meeting/Proxy Form		23/09/13	576.41KB	Share
PAB	PAT-SM6 Receives Orphan Drug Designation for MM	PRICE SENSITIVE	12/09/13	379.27KB	Share
PAB	Change in substantial holding		21/08/13	443.03KB	Share
PAB	Patrys 2013 Annual Report		21/08/13	3.28MB	Share
PAB	Appendix 4E and 2013 Annual Report	PRICE SENSITIVE	21/08/13	3.66MB	Share
PAB	Data from 2nd and 3rd Cohorts in Multiple Myeloma Trial	PRICE SENSITIVE	13/08/13	369.56KB	Share
PAB	Patrys' MM Clinical Trial to Progress to Final Patient Group	PRICE SENSITIVE	07/08/13	362.31KB	Share
PAB	Treatment of 3rd Patient Group in MM Trial Completed	PRICE SENSITIVE	24/07/13	362.9KB	Share
PAB	Appendix 4C - Quarterly Cash Flow - June 2013	PRICE SENSITIVE	19/07/13	156.71KB	Share
PAB	ARC Linkage Grant to Support PAT-SM6 Diagnostics Development	PRICE SENSITIVE	10/07/13	276.96KB	Share
PAB	Further Data on the Effectiveness of PAT-SM6 Published	PRICE SENSITIVE	11/06/13	613.03KB	Share
PAB	Patrys Granted Key Patent for Lead Product PAT-LM1	PRICE SENSITIVE	06/06/13	449.26KB	Share
PAB	PAT-SM6 Kills Human Multiple Myeloma Cells	PRICE SENSITIVE	08/05/13	483.55KB	Share
PAB	Patrys Hosts 2nd IgM Conference		06/05/13	471.89KB	Share
PAB	Patrys Progresses MM Clinical Trial to 3rd Patient Group	PRICE SENSITIVE	24/04/13	360.14KB	Share
PAB	New Data Supports PAT-SM6 Profile as Anti-cancer Treatment	PRICE SENSITIVE	22/04/13	379.63KB	Share
PAB	Appendix 4C - Quarterly Cash Flow - March 2013	PRICE SENSITIVE	19/04/13	157.13KB	Share
PAB	Treatment of Second Patient Group in MM Trial Completed	PRICE SENSITIVE	10/04/13	360.14KB	Share
PAB	Preclinical Results Support PAT-SM6 MM Programme	PRICE SENSITIVE	20/03/13	475.09KB	Share
PAB	Data from 1st Cohort in Multiple Myeloma Trial	PRICE SENSITIVE	07/03/13	366.4KB	Share
PAB	Half Yearly Report and Accounts - December 2012	PRICE SENSITIVE	06/02/13	627.46KB	Share
PAB	Appendix 4C - Quarterly Cash Flow - December 2012	PRICE SENSITIVE	18/01/13	110.05KB	Share
PAB	Patrys Progresses Multiple Myeloma Clinical Trial	PRICE SENSITIVE	14/01/13	314.38KB	Share
PAB	Treatment of First Patient Group in MM Trial Completed	PRICE SENSITIVE	10/12/12	300.01KB	Share
PAB	Patrys CEO Presents at BBY Life Sciences Conference		05/12/12	1.47MB	Share
PAB	Patrys Investor Presentation - November 2012		27/11/12	2.07MB	Share
PAB	Patrys Enrols First Patient in Multiple Myeloma Trial	PRICE SENSITIVE	07/11/12	297.66KB	Share
PAB	Appendix 3B - Correction		02/11/12	122.07KB	Share
PAB	Appendix 3B		02/11/12	92.34KB	Share
PAB	Patrys Receives Australian Ethics Approval for MM Trial	PRICE SENSITIVE	01/11/12	307.54KB	Share

PAB Appendix 4C - Quarterly - 31 December 2014
09/01/15	PRICE SENSITIVE	157.96KB	Share
PAB Becoming a substantial holder
08/12/14		724.87KB	Share
PAB Patrys Presents at AusBiotech Invest 2014
03/12/14		569.96KB	Share
PAB Initial Director's Interest Notice
12/11/14		278.96KB	Share
PAB Results of Meeting
12/11/14		437.43KB	Share
PAB Dr. James Campbell Joins the Patrys Board
12/11/14		428.44KB	Share
PAB Patrys 2014 AGM Presentation
12/11/14		475.79KB	Share
PAB Patrys Provides Update on Clinical Trial
07/11/14	PRICE SENSITIVE	426.23KB	Share
PAB Final Director's Interest Notice - M Roskrow
29/10/14		189.25KB	Share
PAB Patrys Provides Update on CEO Position
29/10/14	PRICE SENSITIVE	416.77KB	Share
PAB Appendix 4C - Quarterly - 30 September 2014
17/10/14	PRICE SENSITIVE	157.58KB	Share
PAB Notice of Annual General Meeting/Proxy Form
10/10/14		443.86KB	Share
PAB Patrys Granted Australian Patent for PAT-LM1
30/09/14	PRICE SENSITIVE	359.8KB	Share
PAB Patrys CEO Resignation
24/09/14	PRICE SENSITIVE	334.26KB	Share
PAB Patrys Investor Presentation - September 2014
18/09/14		1.27MB	Share
PAB Patrys Limited - Open Briefing
16/09/14	PRICE SENSITIVE	274.54KB	Share
PAB Patrys 2014 Annual Report
09/09/14		1.41MB	Share
PAB Preliminary Final Report - 30 June 2014
29/08/14	PRICE SENSITIVE	674.61KB	Share
PAB Patrys - Details of PAT-SM6 & Carfilzomib Clinical Trial
25/08/14	PRICE SENSITIVE	370.28KB	Share
PAB Patrys to Present at German Hematology Congress
18/08/14	PRICE SENSITIVE	124.94KB	Share
PAB Patrys Reports Progress on Preclinical Programmes
24/07/14	PRICE SENSITIVE	476.88KB	Share
PAB Appendix 4C - Quarterly Cash Flow - June 2014
21/07/14	PRICE SENSITIVE	156.5KB	Share
PAB Patrys Granted Third US Patent for PAT-SM6
18/06/14	PRICE SENSITIVE	477.49KB	Share
PABPatrys' CEO Presents at Asia Biotech Invest 2014
04/06/14		1.39MB	Share
PABPositive Response for PAT-SM6 in Combination Therapy
28/05/14	PRICE SENSITIVE	371.59KB	Share
PABAppendix 3B
20/05/14		763KB	Share
PABAppendix 4C - Quarterly Cash Flow - March 2014
11/04/14	PRICE SENSITIVE	156.81KB	Share
PABFirst Plant-based Production of PAT-SM6
02/04/14	PRICE SENSITIVE	511.31KB	Share
PABFinal Data Confirms Successful PAT-SM6 Clinical Trial
27/03/14	PRICE SENSITIVE	378.18KB	Share
PABPAT-LM1 Advancing to the Clinic
24/03/14	PRICE SENSITIVE	383.58KB	Share
PABShare Issue and Cleansing Statement
18/03/14		908.71KB	Share
PABHalf Yearly Report and Accounts - December 2013
12/02/14	PRICE SENSITIVE	856.34KB	Share
PABPatrys Raises a Further $0.9 Million
29/01/14		1.09MB	Share
PABPatrys Provides Shareholder Update
23/01/14	PRICE SENSITIVE	490.29KB	Share
PABPAT-SC1 Clinical Trial 10 Year Follow Up Data Published
22/01/14	PRICE SENSITIVE	366.1KB	Share
PABAppendix 4C - Quarterly Cash Flow - December 2013
21/01/14	PRICE SENSITIVE	156.59KB	Share
PABPatrys Raises a Further $1.3 Million
14/01/14	PRICE SENSITIVE	911.84KB	Share
PABChange in substantial holding
06/01/14		388.05KB	Share
PABChange in substantial holding
20/12/13		95.95KB	Share
PABChange of Director's Interest Notice
19/12/13		204.5KB	Share
PABChange of Director's Interest Notice
19/12/13		204.68KB	Share
PABChange of Director's Interest Notice
19/12/13		206.13KB	Share
PABChange of Director's Interest Notice
19/12/13		208.12KB	Share
PABAppendix 3B - Rights Issue
19/12/13		492.32KB	Share
PABPatrys Raises $5.5m from Rights Issue
16/12/13		288.41KB	Share
PABData from Final Cohort of Patients in MM Clinical Trial
29/11/13	PRICE SENSITIVE	483.66KB	Share
PABRights Issue Offer Documents Mailed to Shareholders
27/11/13		247.52KB	Share
PABRights Issue Offer Document
27/11/13	PRICE SENSITIVE	462.17KB	Share
PABAppendix 3B
20/11/13		488.94KB	Share
PABPatrys Presents at BBY Life Sciences Conference
19/11/13		1.22MB	Share
PABPatrys Granted Australian Patent for PAT-SM6
18/11/13	PRICE SENSITIVE	365.15KB	Share
PABAppendix 3B
15/11/13		488.37KB	Share
PABAppendix 3B
14/11/13		488.12KB	Share
PABLetter to Ineligible Shareholders
14/11/13		340.63KB	Share
PABLetter to Eligible Shareholders
14/11/13		180.24KB	Share
PABLetter to Optionholders
13/11/13		145.93KB	Share
PABCleansing Statement
13/11/13		326.45KB	Share
PABAppendix 3B
13/11/13		493.33KB	Share
PABPatrys Announces $12.5 Million Rights Issue
13/11/13	PRICE SENSITIVE	408.37KB	Share
PABPatrys to Initiate Clinical Trial with Onyx Pharmaceuticals
11/11/13	PRICE SENSITIVE	469.72KB	Share
PABPatrys Granted US Patent for Lead Product PAT-LM1
08/11/13	PRICE SENSITIVE	355.39KB	Share
PABUSA FDA Grants Orphan Drug Status for PAT-SM6
06/11/13	PRICE SENSITIVE	361.86KB	Share
PABFinal Director's Interest Notice
23/10/13		236.64KB	Share
PABResults of Meeting
23/10/13		512.3KB	Share
PABCEO Presentation to 2013 AGM
23/10/13		964.21KB	Share
PABAppendix 4C - Quarterly Cash Flow - September 2013
18/10/13	PRICE SENSITIVE	34.88KB	Share
PABRetirement of Director - Dr. Alan Robertson
18/10/13		420.63KB	Share
PABPatrys Limited - Open Briefing
14/10/13		128.88KB	Share
PABPatrys to Present at ASH International Conference
10/10/13		481.72KB	Share
PABPatrys CEO Presents at BIO Investor Forum
09/10/13		1.83MB	Share
PABNotice of Annual General Meeting/Proxy Form
23/09/13		576.41KB	Share
PABPAT-SM6 Receives Orphan Drug Designation for MM
12/09/13	PRICE SENSITIVE	379.27KB	Share
PABChange in substantial holding
21/08/13		443.03KB	Share
PABPatrys 2013 Annual Report
21/08/13		3.28MB	Share
PABAppendix 4E and 2013 Annual Report
21/08/13	PRICE SENSITIVE	3.66MB	Share
PABData from 2nd and 3rd Cohorts in Multiple Myeloma Trial
13/08/13	PRICE SENSITIVE	369.56KB	Share
PABPatrys' MM Clinical Trial to Progress to Final Patient Group
07/08/13	PRICE SENSITIVE	362.31KB	Share
PABTreatment of 3rd Patient Group in MM Trial Completed
24/07/13	PRICE SENSITIVE	362.9KB	Share
PABAppendix 4C - Quarterly Cash Flow - June 2013
19/07/13	PRICE SENSITIVE	156.71KB	Share
PABARC Linkage Grant to Support PAT-SM6 Diagnostics Development
10/07/13	PRICE SENSITIVE	276.96KB	Share
PABFurther Data on the Effectiveness of PAT-SM6 Published
11/06/13	PRICE SENSITIVE	613.03KB	Share
PABPatrys Granted Key Patent for Lead Product PAT-LM1
06/06/13	PRICE SENSITIVE	449.26KB	Share
PABPAT-SM6 Kills Human Multiple Myeloma Cells
08/05/13	PRICE SENSITIVE	483.55KB	Share
PABPatrys Hosts 2nd IgM Conference
06/05/13		471.89KB	Share
PABPatrys Progresses MM Clinical Trial to 3rd Patient Group
24/04/13	PRICE SENSITIVE	360.14KB	Share
PABNew Data Supports PAT-SM6 Profile as Anti-cancer Treatment
22/04/13	PRICE SENSITIVE	379.63KB	Share
PABAppendix 4C - Quarterly Cash Flow - March 2013
19/04/13	PRICE SENSITIVE	157.13KB	Share
PABTreatment of Second Patient Group in MM Trial Completed
10/04/13	PRICE SENSITIVE	360.14KB	Share
PABPreclinical Results Support PAT-SM6 MM Programme
20/03/13	PRICE SENSITIVE	475.09KB	Share
PABData from 1st Cohort in Multiple Myeloma Trial
07/03/13	PRICE SENSITIVE	366.4KB	Share
PABHalf Yearly Report and Accounts - December 2012
06/02/13	PRICE SENSITIVE	627.46KB	Share
PABAppendix 4C - Quarterly Cash Flow - December 2012
18/01/13	PRICE SENSITIVE	110.05KB	Share
PABPatrys Progresses Multiple Myeloma Clinical Trial
14/01/13	PRICE SENSITIVE	314.38KB	Share
PABTreatment of First Patient Group in MM Trial Completed
10/12/12	PRICE SENSITIVE	300.01KB	Share
PABPatrys CEO Presents at BBY Life Sciences Conference
05/12/12		1.47MB	Share
PABPatrys Investor Presentation - November 2012
27/11/12		2.07MB	Share
PABPatrys Enrols First Patient in Multiple Myeloma Trial
07/11/12	PRICE SENSITIVE	297.66KB	Share
PABAppendix 3B - Correction
02/11/12		122.07KB	Share
PABAppendix 3B
02/11/12		92.34KB	Share
PABPatrys Receives Australian Ethics Approval for MM Trial
01/11/12	PRICE SENSITIVE	307.54KB	Share

REFRESH

First 3 4 5 6 7

(20min delay)
Last 0.9¢		Change 0.000(0.00%)		Mkt cap ! $18.51M

Open	High	Low	Value	Volume
0.9¢	0.9¢	0.9¢	$18.68K	2.075M

Buyers (Bids)

No.	Vol.	Price($)
11	2642383	0.8¢

Sellers (Offers)

Price($)	Vol.	No.
0.9¢	856022	2

View Market Depth

No.	Vol.	Price($)
11	2642383	0.008
17	4746715	0.007
11	2787680	0.006
8	3144992	0.005
5	4324000	0.004

Price($)	Vol.	No.
0.009	856022	2
0.010	1830082	5
0.011	1380000	4
0.012	372407	3
0.013	990000	2

Last trade - 16.10pm 26/04/2024 (20 minute delay)


Last 0.9¢		Change 0.000 ( 0.00 %)
Open	High	Low	Volume
0.9¢	0.9¢	0.9¢	97616
Last updated 11.58am 26/04/2024 ?

PAB (ASX) Chart

PATRYS LIMITED - Announcements

Corporate SpotlightNot Yet Available

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories

Corporate Spotlight
Not Yet Available